Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Mereo BioPharma Group plc는 영국과 미국에서 희귀 질환 치료제를 개발하고 상용화하는 바이오제약 회사입니다. 이 회사는 골형성부전증 치료를 위한 항체 Setrusumab, 알파-1 항트립신 결핍 관련 폐 질환 치료를 위해 임상 2상 시험 중인 경구용 저분자 화합물 Alvelestat, 그리고 상염색체 우성 골화석증 2형 치료를 위한 항-FZD 단일클론 항체 Vantictumab을 개발하고 있습니다. 또한, 성선자극호르몬 결핍 성선기능저하증 치료를 위해 임상 2상 시험 중인 경구용 아로마타제 억제제 Leflutrozole, 말기 난소암 치료를 위한 임상 1b상 시험을 완료한 Navicixizumab, 진행성 고형암 치료를 위해 면역 세포의 인간 TIGIT 수용체에 결합하는 IgG1 단일클론 항체 Etigilimab, 그리고 만성 폐쇄성 폐 질환의 급성 악화 치료를 위해 임상 2상 시험 중인 p38 MAP 키나아제